Blueprint Medicines (BPMC) News Today $88.69 -6.96 (-7.28%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Blueprint Medicines Co. (NASDAQ:BPMC) Short Interest UpdateBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 4,130,000 shares, an increase of 14.1% from the October 15th total of 3,620,000 shares. Based on an average trading volume of 607,600 shares, the short-interest ratio is currently 6.8 days.November 16 at 3:27 PM | marketbeat.comBlueprint Medicines’ Promising Pipeline Developments Support Buy RatingNovember 16 at 11:30 AM | markets.businessinsider.comBlueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Rating of "Moderate Buy" from AnalystsBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) has received an average rating of "Moderate Buy" from the twenty-one analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recNovember 16 at 1:41 AM | marketbeat.comBlueprint Medicines: Hold Rating Amidst Future Research Potential and Clinical UncertaintiesNovember 16 at 1:21 AM | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Blueprint Medicines (BPMC)November 16 at 1:21 AM | markets.businessinsider.comBlueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology DrugsNovember 15 at 6:13 PM | seekingalpha.comBlueprint Medicines' (BPMC) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $135.00 price objective on shares of Blueprint Medicines in a research note on Friday.November 15 at 8:50 AM | marketbeat.comBlueprint Medicines' (BPMC) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research note on Friday.November 15 at 8:30 AM | marketbeat.comJP Morgan Initiates Coverage of Blueprint Medicines (BPMC) with Overweight RecommendationNovember 15 at 2:16 AM | msn.comBlood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': AnalystNovember 14 at 3:18 PM | benzinga.comBlueprint Medicines initiated with an Overweight at JPMorganNovember 14 at 11:09 AM | msn.comJPMorgan Chase & Co. Initiates Coverage on Blueprint Medicines (NASDAQ:BPMC)JPMorgan Chase & Co. started coverage on Blueprint Medicines in a research report on Thursday. They issued an "overweight" rating and a $126.00 price target on the stock.November 14 at 7:38 AM | marketbeat.comEntropy Technologies LP Buys New Shares in Blueprint Medicines Co. (NASDAQ:BPMC)Entropy Technologies LP purchased a new position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,800 shares of the biotechnology company's stock, valued aNovember 14 at 4:46 AM | marketbeat.com10,800 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Acquired by Entropy Technologies LPEntropy Technologies LP acquired a new stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 10,800 shares of the biotechnology company's stock, valued at aNovember 14 at 4:46 AM | marketbeat.comUS Bancorp DE Acquires 7,137 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)US Bancorp DE increased its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 147.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,971 shares of the biotechnology company's stock after purchNovember 9, 2024 | marketbeat.com97,861 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Bought by M&G PlcM&G Plc purchased a new stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 97,861 shares of the biotechnology company's stock, valued at approximately $9November 8, 2024 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Upgraded at StockNews.comStockNews.com raised Blueprint Medicines from a "sell" rating to a "hold" rating in a research note on Friday.November 8, 2024 | marketbeat.comBlueprint should rally on today’s Cogent data, says OppenheimerNovember 6, 2024 | markets.businessinsider.comQ1 Earnings Forecast for BPMC Issued By HC WainwrightBlueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Blueprint Medicines in a research note issued on Thursday, October 31st. HC Wainwright analyst A. Fein forecasts that the biotechnology company will pNovember 4, 2024 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by Emerald Advisers LLCEmerald Advisers LLC increased its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 10.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 375,866 shares of the biotechnology company's stNovember 3, 2024 | marketbeat.comAnalysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter ReportNovember 2, 2024 | finance.yahoo.comQ4 EPS Estimates for Blueprint Medicines Raised by WedbushBlueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Analysts at Wedbush upped their Q4 2024 EPS estimates for Blueprint Medicines in a report issued on Wednesday, October 30th. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will post earnings per share of ($0.66) fNovember 1, 2024 | marketbeat.comQ3 2024 Blueprint Medicines Corp Earnings CallNovember 1, 2024 | finance.yahoo.comBlueprint Medicines: Strong Ayvakit Sales and International Growth Drive Hold Rating Amid Awaited Pipeline DataNovember 1, 2024 | markets.businessinsider.comBlueprint Medicines: Strong Growth Prospects with Ayvakit and Pipeline InnovationsOctober 31, 2024 | markets.businessinsider.comBlueprint Medicines: Strong Financial Performance and Strategic Initiatives Drive Buy RatingOctober 31, 2024 | markets.businessinsider.comBlueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ...October 31, 2024 | finance.yahoo.comBlueprint Medicines Reports Strong Q3 2024 ResultsOctober 31, 2024 | markets.businessinsider.comBlueprint Medicines (BPMC) Receives a Buy from Wells FargoOctober 31, 2024 | markets.businessinsider.comBlueprint Medicines Corporation (NASDAQ:BPMC) Q3 2024 Earnings Call TranscriptOctober 31, 2024 | msn.comWedbush Research Analysts Lift Earnings Estimates for BPMCBlueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Wedbush increased their FY2026 EPS estimates for shares of Blueprint Medicines in a report released on Wednesday, October 30th. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will post earnings per share of $2.05October 31, 2024 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Shares Gap Up - Here's WhyBlueprint Medicines (NASDAQ:BPMC) Shares Gap Up - Time to Buy?October 30, 2024 | marketbeat.comNeedham & Company LLC Reaffirms Buy Rating for Blueprint Medicines (NASDAQ:BPMC)Needham & Company LLC reiterated a "buy" rating and issued a $133.00 price target on shares of Blueprint Medicines in a research note on Wednesday.October 30, 2024 | marketbeat.comBlueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidanceOctober 30, 2024 | prnewswire.comBarclays Remains a Hold on Blueprint Medicines (BPMC)October 29, 2024 | markets.businessinsider.comBlueprint Medicines Q3 2024 Earnings PreviewOctober 29, 2024 | msn.comAssenagon Asset Management S.A. Lowers Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)Assenagon Asset Management S.A. reduced its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 39.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 100,633 shares of the biotechnologyOctober 28, 2024 | marketbeat.comBlueprint Medicines initiated with a Neutral at UBSOctober 25, 2024 | markets.businessinsider.comUBS Initiates Coverage of Blueprint Medicines (BPMC) with Neutral RecommendationOctober 25, 2024 | msn.comPiper Sandler Sticks to Its Hold Rating for Blueprint Medicines (BPMC)October 24, 2024 | markets.businessinsider.comUBS Group Begins Coverage on Blueprint Medicines (NASDAQ:BPMC)UBS Group started coverage on shares of Blueprint Medicines in a research note on Thursday. They set a "neutral" rating and a $88.00 price target for the company.October 24, 2024 | marketbeat.comBlueprint Medicines (BPMC) to Release Quarterly Earnings on WednesdayBlueprint Medicines (NASDAQ:BPMC) will be releasing earnings before the market opens on Wednesday, October 30, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=636292)October 23, 2024 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by SG Americas Securities LLCSG Americas Securities LLC cut its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 88.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,521 shares of the biotechnology cOctober 22, 2024 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Given Average Rating of "Moderate Buy" by AnalystsShares of Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) have been given an average rating of "Moderate Buy" by the nineteen ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have assigned a holOctober 22, 2024 | marketbeat.comBlueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024October 16, 2024 | prnewswire.comEssex Investment Management Co. LLC Buys Shares of 35,461 Blueprint Medicines Co. (NASDAQ:BPMC)Essex Investment Management Co. LLC purchased a new stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 35,461 shares of the biotechnologyOctober 13, 2024 | marketbeat.comMorgan Stanley Sticks to Its Hold Rating for Blueprint Medicines (BPMC)October 12, 2024 | markets.businessinsider.comBlueprint Medicines Co. (NASDAQ:BPMC) Forecasted to Post Q2 2026 Earnings of $0.34 Per ShareBlueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Investment analysts at Zacks Research raised their Q2 2026 earnings per share estimates for shares of Blueprint Medicines in a research note issued on Wednesday, October 9th. Zacks Research analyst A. Chakraborty now anticipates that the bioteOctober 11, 2024 | marketbeat.comDimensional Fund Advisors LP Sells 16,619 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Dimensional Fund Advisors LP lowered its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 34.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 31,979 shares of the biotechnology company's sOctober 11, 2024 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.com Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address The Tesla Trade Is Back In Business (Ad)If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla. Discover how to trade Tesla, simply follow this link here. BPMC Media Mentions By Week BPMC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BPMC News Sentiment▼0.690.56▲Average Medical News Sentiment BPMC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BPMC Articles This Week▼206▲BPMC Articles Average Week Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DCPH News Today CLDX News Today SDGR News Today EBS News Today INCY News Today TEVA News Today BGNE News Today MRNA News Today VTRS News Today SMMT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BPMC) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
